Merestinib In Non-Small Cell Lung Cancer And Solid Tumors
Status:
Active, not recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This research study is examining merestinib (a targeted therapy) as a possible treatment for
non-small cell lung cancer (NSCLC) that was found to have a specific change in the MET gene
(a MET exon 14 mutation); or as a treatment for solid tumors that have an alteration in the
NTRK gene (an NTRK1, 2, or 3 rearrangement).